• 專利部分：

GRAPHICAL USER INTERFACE OF DISPLAY SCREEN(美國專利案核准案號：US 29/777,391）
Method of identification of methicillin-resistant Staphylococcus aureus (美國專利案核准案號：US11352655B2；臺灣專利證書號數I775205，公告日期2022.08.22)

• 國際期刊論文發表：

Yu J, Tien N, Liu YC, Cho DY, Chen JW, Tsai YT, et al. Rapid identification of methicillin-resistant Staphylococcus aureus using MALDI-TOF MS and machine learning from over 20,000 clinical isolates. Microbiol Spectr 2022;10(2):e0048322.
Lee YL, Chen HM, Hii IM, Hsueh PR. Carbapenemase-producing Enterobacterales infections: Recent advances in diagnosis and treatment. Int J Antimicrob Agents. 2022;59(2):106528.
Lee YL, Ko WC, Hsueh PR. Geographic patterns of carbapenem-resistant Pseudomonas aeruginosa in the Asia-Pacific region: Results from the antimicrobial testing leadership and surveillance (ATLAS) program, 2015-2019. Antimicrob Agents Chemother. 2022;66(2):e0200021.
Huang YT, Kuo YW, Lee NY, Tien N, Liao CH, Teng LJ, et al. SMART study group. Evaluating NG-Test CARBA 5 multiplex immunochromatographic and cepheid Xpert CARBA-R assays among carbapenem-resistant Enterobacterales isolates associated with bloodstream infection. Microbiol Spectr. 2022;10(1):e0172821.
Jean SS, Ko WC, Lu MC, Lee WS, Hsueh PR; SMART Program. Multicenter surveillance of in vitro activities of cefepime-zidebactam, cefepime-enmetazobactam, omadacycline, eravacycline, and comparator antibiotics against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii complex causing bloodstream infection in Taiwan, 2020. Expert Rev Anti Infect Ther. 2022;20(6):941-953.
Lee YL, Ko WC, Lee WS, Lu PL, Chen YH, Cheng SH, et al. In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020. Int J Antimicrob Agents. 2021;58(3):106377.
Lai CC, Chen SY, Ko WC, Hsueh PR. Increased antimicrobial resistance during the COVID-19 pandemic. Int J Antimicrob Agents. 2021;57(4):106324.
Chiang HY, Chen TC, Lin CC, Ho LC, Kuo CC, Chi CY. Trend and predictors of short-term mortality of adult bacteremia at emergency departments: A 14-Year cohort study of 14,625 patients. Open Forum Infectious Diseases. 2021;8(11): ofab485.
Hsu YL, Chang SN, Lin CC, Lin HC, Lai HC, Kuo CC, et al. Clinical characteristics and prediction analysis of pediatric urinary tract infections caused by Gram-positive bacteria. Scientific Reports.2021;11(1):11010.
Lai HC, Chang SN, Lin HC, Hsu YL, Wei HM, Kuo CC, et al. Association between urine pH and common uropathogens in children with urinary tract infections. J Microbiol Immunol Infect. 2021;54(2):290-298.
Liu PY, Lee YL, Lu MC, Shao PL, Lu PL, Chen YH, et al. National surveillance of antimicrobial susceptibility of bacteremic Gram-negative bacteria with emphasis on community-acquired resistant isolates: Report from the 2019 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART). Antimicrob Agents Chemother. 2020;64(10): e01089-20.
Chiang HY, Huang HC, Chung CW, Yeh YC, Chen YC, Tien N, et al. Risk prediction for 30-day mortality among patients with Clostridium difficile infections: A retrospective cohort study. Antimicrobial Resistance & Infection Control. 2019; 8:175.
Lin HH, Tseng KH, Tien N, Lin YT, Hsueh PR. Evaluation of the Rapid Sepsityper protocol and specific MBT-Sepsityper module for the identification of bacteremia and fungemia using Bruker Biotyper MALDI-TOF MS. J Microbiol Immunol Infect. 2022: S1684-1182(22)00103-7.
Wu YL, Chen Y, Xu DH, Chou CH, Chang T, Weng Y, et al. A System for sepsis detection and mortality prediction based on a machine learning algorithm using common features (under review).
Yu J, Lin YZ, Chen WC, Tseng KH, Lin HH, Tien N, et al. Direct prediction of carbapenem non-susceptible, carbapenemase-producing, and colistin-resistant Klebsiella pneumoniae isolates from routine MALDI-TOF mass spectra using machine learning and outcome evaluation (under review).

• 國際演講

2023.06 2023 Asia Pacific Society of Clinical Microbiology and Infection ”Global threat of carbapenem-resistant GNB” 薛博仁副院長和 “MALDI-TOF MS & machine learning for colistin-resistance” 游家鑫主任 https://www.apccmi2023.com/program/scientific.php
2022.11 德國MEDICA2022 「臨床決策輔助系統於感染菌種與抗藥風險預測」游家鑫主任 https://www.medica-tradefair.com/